Establishment of prophylactic vaccination for bladder cancer
| Project/Area Number |
23592342
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATO Noriyuki 札幌医科大学, 医学部, 教授 (50158937)
TORIGOE Toshihiko 札幌医科大学, 医学部, 准教授 (20301400)
MASUMORI Naoya 札幌医科大学, 医学部, 教授 (20295356)
塚本 泰司 札幌医科大学, 医学部, 名誉教授 (50112454)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 腫瘍学 / がんワクチン / 膀胱癌 / 再発予防 / 腫瘍抗原 |
|---|
| Research Abstract |
Peptides SVNC-S, containing an MHC class I-restricted epitope, and SVNC-L, containing MHC class I- and II-restricted epitopes, were derived from the amino acid sequence of survivin. Vaccination with SVNC-L induced a more powerful immune response than that with SVNC-S. The SVNC-L vaccination resulted in more significant suppression of the tumour growth than vaccination with SVNC-S. The SVNC-L vaccination also prevented BBN-induced bladder carcinogenesis.
|
Report
(4 results)
Research Products
(20 results)
-
-
-
[Journal Article] Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma2013
Author(s)
Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, Tanaka T, Masumori N, Sato N, Tsukamoto T
-
Journal Title
Virchows Arch
Volume: 462
Issue: 1
Pages: 101-107
DOI
Related Report
Peer Reviewed
-
[Journal Article] Potential survival benefit of anti-apoptosis protein, survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer: results from phase I clinical trials2013
Author(s)
Tanaka T, Kitamura H, Inoue R, Nishida S, Takahashi-Takaya A, Kawami S, Torigoe S, Hirohashi Y, Tsukamoto T, Sato N, Masumori N
-
Journal Title
Clin Dev Immunol
Volume: 2013
Pages: 262967-262967
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
